Showing 761 - 780 results of 855 for search '"Houston"', query time: 0.05s Refine Results
  1. 761
  2. 762
  3. 763
  4. 764
  5. 765
  6. 766
  7. 767

    Evaluation of Real-World Evidence to Assess Effectiveness Outcomes of Janus Kinase Inhibitors for Rheumatoid Arthritis: A Systematic Review of US Studies by Gandy C, Bazzazzadehgan S, Bruera S, Huang Y

    Published 2025-01-01
    “…Chandler Gandy,1 Shadi Bazzazzadehgan,1 Sebastian Bruera,2 Yinan Huang1 1Department of Pharmacy Administration, University of Mississippi School of Pharmacy, University, MS, 38677 USA; 2Section of Immunology, Allergy & Rheumatology, Baylor College of Medicine, Houston, TX, USACorrespondence: Yinan Huang, Department of Pharmacy Administration, University of Mississippi School of Pharmacy, University, Faser Hall 235, Oxford, MS, 38677, USA, Tel +1 (662) 915-2173, Email yhuang9@olemiss.eduObjective: This review summarized the real-world effectiveness outcomes of Janus kinase inhibitors (JAKi) for rheumatoid arthritis (RA) based on observational studies.Methods: A systematic review followed PRISMA guidelines, with searches conducted in PubMed, Embase, and CINAHL from each database’s inception to June 2, 2023. …”
    Get full text
    Article
  8. 768

    Current concepts of chronic gastritis and gastropathies: new international consensus RE.GA.IN by S.M. Tkach, N.V. Kharchenko, A.E. Dorofieiev, Yu.Z. Hurkalo, L.M. Ryzhiy

    Published 2024-12-01
    “…In addition to the Sydney and Houston gastritis classifications, the six editions of the Maastricht Consensus (1996–2022) and the Kyoto Global Consensus deserve special attention, thanks to which broad agreements and significant scientific achievements became possible in the most controversial issues of the entire spectrum of gastritis, with a special emphasis on H.pylori gastritis, which accounts for more than 90 % of all forms of gastritis worldwide. …”
    Get full text
    Article
  9. 769

    Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States by Finn RS, Iyer R, Kalman RS, Parikh ND, Cabrera R, Babajanyan S, Kaseb AO

    Published 2025-02-01
    “…Richard S Finn,1 Renuka Iyer,2 Richard S Kalman,3 Neehar D Parikh,4 Roniel Cabrera,5 Svetlana Babajanyan,6 Ahmed O Kaseb7 1Department of Medicine, University of California, Los Angeles, CA, USA; 2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA; 3Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA; 4Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA; 5Department of Medicine, University of Florida Health, Gainesville, FL, USA; 6US Medical Affairs, Oncology, Bayer Healthcare, Whippany, NJ, USA; 7Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Richard S Finn, Department of Medicine, University of California, Los Angeles, CA, USA, Tel +1-310-586-2091, Email rfinn@mednet.ucla.eduIntroduction: While several systemic therapies are available for unresectable hepatocellular carcinoma (uHCC), there is a lack of granular real-world evidence to support the efficacy and safety of these therapies. …”
    Get full text
    Article
  10. 770
  11. 771
  12. 772
  13. 773
  14. 774
  15. 775
  16. 776
  17. 777
  18. 778
  19. 779
  20. 780